Medicare Enrolled
Dr. Brian Ulrich, M.D.
Medical Oncology · Wichita Falls, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Ulrich from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ulrich? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Ulrich
Dr. Brian Ulrich is a medical oncology in Wichita Falls, TX, with 20 years in practice. Based on federal Medicare data, Dr. Ulrich performed 327,937 Medicare services across 3,538 unique beneficiaries.
Between the years covered by Open Payments, Dr. Ulrich received a total of $4,921 from 54 pharmaceutical and/or device companies across 129 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Ulrich is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 1% volume in TX$ $4,921 industry payments
Medicare Practice Summary
Medicare Utilization ↗327,937
Medicare services
Top 1% in TX for medical oncology
3,538
Unique beneficiaries
$4
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~16,397 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 183,600 | $0 | $5 |
| Darbepoetin injection (Aranesp) for anemia | 48,695 | $2 | $20 |
| Filgrastim injection (Nivestym) for white blood cells | 36,240 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 16,400 | $43 | $137 |
| Azacitidine chemotherapy injection | 11,300 | $0 | $13 |
| Iron sucrose injection (Venofer) | 7,200 | $0 | $2 |
| Paclitaxel chemotherapy injection | 6,552 | $0 | $8 |
| Contrast dye for imaging (iodine-based) | 3,536 | $0 | $3 |
| Denosumab injection (Prolia/Xgeva) | 2,040 | $19 | $67 |
| Dexamethasone injection (steroid) | 1,899 | $0 | $1 |
| Injection, granisetron hydrochloride, 100 mcg | 1,430 | $0 | $24 |
| Blood draw (venipuncture) | 790 | $8 | $20 |
| Complete blood count (CBC) with differential | 770 | $8 | $36 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 672 | $82 | $1,348 |
| Office visit, established patient (20-29 min) | 594 | $61 | $250 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 538 | $47 | $313 |
| Comprehensive metabolic blood panel | 511 | $10 | $64 |
| Injection of additional new drug or substance into vein | 462 | $11 | $108 |
| Anti-nausea injection (Aloxi/palonosetron) | 410 | $1 | $114 |
| Administration of chemotherapy into vein, 1 hour or less | 389 | $95 | $707 |
| Drug injection, under skin or into muscle | 380 | $10 | $96 |
| Injection, zoledronic acid, 1 mg | 303 | $7 | $431 |
| Injection, magnesium sulfate, per 500 mg | 260 | $1 | $6 |
| Ferritin level test (iron stores) | 219 | $13 | $60 |
| Injection, carboplatin, 50 mg | 219 | $2 | $300 |
| Iron level test | 210 | $6 | $27 |
| Iron binding capacity test | 210 | $9 | $35 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 152 | $55 | $211 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 146 | $21 | $157 |
| Irrigation of implanted venous access drug delivery device | 123 | $18 | $114 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 108 | $272 | $2,762 |
| Administration of additional new drug or substance into vein, 1 hour or less | 103 | $48 | $344 |
| Complete blood count (CBC), automated | 101 | $6 | $34 |
| Microscopic examination for white blood cells with manual cell count | 100 | $4 | $22 |
| Injection, diphenhydramine hcl, up to 50 mg | 95 | $1 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 86 | $16 | $100 |
| Administration of chemotherapy into vein, each additional hour | 79 | $20 | $161 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 78 | $24 | $145 |
| Unclassified drugs | 73 | $1 | $8 |
| Red blood count, automated test | 71 | $4 | $23 |
| Office visit, established patient (30-39 min) | 69 | $86 | $368 |
| Lactate dehydrogenase (enzyme) level | 64 | $6 | $31 |
| Application of on-body injector for under skin injection | 57 | $14 | $96 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 52 | $1 | $19 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 48 | $133 | $3,675 |
| Infusion, normal saline solution , 1000 cc | 45 | $2 | $19 |
| PSA test (prostate cancer screening) | 44 | $18 | $94 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 44 | $20 | $128 |
| New patient office visit (30-44 min) | 44 | $75 | $372 |
| Hospital follow-up visit, low complexity | 38 | $37 | $135 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 37 | $311 | $1,722 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 35 | $178 | $700 |
| Drawing of blood for a medical problem | 33 | $66 | $264 |
| Ct scan of chest with contrast | 26 | $53 | $821 |
| Red blood count automated, with additional calculations | 26 | $5 | $26 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev | 26 | $177 | $700 |
| Infusion into a vein for hydration, 31-60 minutes | 24 | $23 | $256 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 24 | $4 | $25 |
| CT scan of abdomen and pelvis with contrast | 18 | $168 | $1,067 |
| Blood creatinine level | 17 | $5 | $31 |
| New patient office visit (45-59 min) | 11 | $111 | $565 |
| Initial hospital admission, moderate complexity | 11 | $93 | $470 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
56.3% high complexity
42.4% medium
1.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,921
Total received (2018-2024)
Avg $703/year across 7 years
Top 47% in TX for medical oncology
54
Companies
129
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,770 (96.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$152 (3.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$479
2023$1,211
2022$873
2021$902
2020$221
2019$632
2018$605
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$336
Boehringer Ingelheim Pharmaceuticals, Inc.
$301
Takeda Pharmaceuticals U.S.A., Inc.
$256
Lilly USA, LLC
$246
PFIZER INC.
$224
GlaxoSmithKline, LLC.
$222
Exelixis Inc.
$214
Adaptive Biotechnologies Corporation
$209
Incyte Corporation
$182
Blueprint Medicines Corporation
$167
Kite Pharma, Inc.
$149
Celgene Corporation
$134
Seattle Genetics, Inc.
$131
Pharmacyclics LLC, An AbbVie Company
$130
Janssen Scientific Affairs, LLC
$119
Novo Nordisk Inc
$117
Rigel Pharmaceuticals, Inc.
$116
Karyopharm Therapeutics Inc.
$114
Merck Sharp & Dohme LLC
$114
Chiesi USA, Inc.
$101
Janssen Biotech, Inc.
$101
E.R. Squibb & Sons, L.L.C.
$93
GENZYME CORPORATION
$86
Amgen Inc.
$86
Novartis Pharmaceuticals Corporation
$72
Lexicon Pharmaceuticals, Inc.
$67
Astellas Pharma US Inc
$66
Sun Pharmaceutical Industries Inc.
$60
PUMA BIOTECHNOLOGY, INC.
$59
Bayer HealthCare Pharmaceuticals Inc.
$52
AVEO Pharmaceuticals, Inc.
$45
Gilead Sciences, Inc.
$45
ABBVIE INC.
$38
Daiichi Sankyo Inc.
$36
Acrotech Biopharma LLC
$36
Ipsen Biopharmaceuticals, Inc
$34
ImmunoGen, Inc.
$27
ADC Therapeutics America, Inc.
$25
Eisai Inc.
$25
TerSera Therapeutics LLC
$25
Dendreon Pharmaceuticals LLC
$24
Seagen Inc.
$23
PharmaEssentia USA Corporation
$23
AbbVie Inc.
$20
Pharmacosmos Therapeutics Inc.
$19
EMD Serono, Inc.
$19
CTI BioPharma Corp.
$18
Sobi, Inc
$18
Regeneron Healthcare Solutions, Inc.
$18
Agios Pharmaceuticals, Inc.
$18
Apellis Pharmaceuticals, Inc.
$17
Stemline Therapeutics Inc.
$15
Jazz Pharmaceuticals Inc.
$13
Bayer Healthcare Pharmaceuticals Inc.
$13
Top 3 companies account for 18.2% of total payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · BAVENCIO · BELEODAQ · BESREMI · BOSULIF · CALQUENCE · CARVYKTI · CLEVIPREX · CYRAMZA · Cabometyx · DARZALEX · DAURISMO · DOPTELET · ENJAYMO · EPKINLY · ERLEADA · Elahere · Empaveli · Enhertu · FARXIGA · FOTIVDA · Fabhalta · GAVRETO · GILOTRIF · IBRANCE · IMFINZI · Imbruvica · Inpefa · JAKAFI · JARDIANCE · JAYPIRCA · JEMPERLI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LUTATHERA · Lenvima · MONJUVI · MONOFERRIC · NERLYNX · NINLARO · Nubeqa · OJJAARA · Odomzo · Orserdu · PADCEV · PEMAZYRE · PLUVICTO · PROVENGE · Padcev · Pomalyst · RYBELSUS · Revlimid · SARCLISA · SOMATULINE DEPOT · TAGRISSO · TALZENNA · TRUMENBA · Tavalisse · Tazverik · Trodelvy · VENCLEXTA · VERZENIO · Vonjo · WELIREG · XPOVIO · XTANDI · Xofigo · Yescarta · ZEJULA · ZEPZELCA · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $2 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
3
Per 100K population
34.3
County median income
$71,958
Nearest hospital
KELL WEST REGIONAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Ulrich is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Ulrich experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Ulrich performed 183,600 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ulrich receive payments from pharmaceutical companies?
Yes. Dr. Ulrich received a total of $4,921 from 54 companies across 129 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ulrich's costs compare to other medical oncologys in Wichita Falls?
Dr. Ulrich's average Medicare payment per service is $4. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ulrich) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Wichita Falls
Browse medical oncologys in Wichita Falls ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc..
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology